Categories: All postsCleantech

Eguana Technologies has 268 per cent upside, Mackie Research says

Look for Eguana Technologies’ (Eguana Technologies Stock Quote, Chart TSXV:EGT) stock to jump in the new year, says analyst Nikhil Thadani of Mackie Research, who sees the company’s order intake trending upwards over the latter half of 2018.

On Monday, Calgary-based Eguana announced it has been approved for South Australia’s Home Battery Scheme as well as state-owned Clean Energy Finance Corporation’s financing program to produce Eguana’s Evolve home battery systems. The two programs will provide an estimated 40,000 households with access to A$100 million in subsidies and low interest loans for residential battery storage.

Thadani says the Home Battery Scheme should add about $5 million to Eguana’s order intake for early 2019, which is double its existing order book.

“Order intake has seen a strong step up in recent months, as the company translates orders into revenue, likely in Q2 (March) F2019,” Thadani said in an update to clients on Monday. “In other words, in the March 2019 quarter, we expect the stock price to react positively, as the stock has been range bound in the ~19-22¢ range in recent months.”

“Medium term, a 10 per cent penetration in South Australia implies a ~$12 million revenue opportunity for EGT versus F2018 (Sept) revenue of ~$4 million and recent order intake of ~$6 million in H2 C2018,” the analyst says.

Thadani has made no change to his “Speculative Buy” rating and $0.70 price target, representing a projected 12-month return of 268 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: egt
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Buy ATS ahead of Q4 earnings, Stifel says

Ahead of the company's fourth quarter earnings report, due May 16, Stifel analyst Justin Keywood says ATS Corp (ATS Corp… [Read More]

41 mins ago

Ormat Technologies is a buy, Roth says

Its first quarter results are in the books and Roth MKM analyst Justin Clare thinks there is money to be… [Read More]

3 hours ago

Cannabist stock is a buy, Beacon says

Beacon analyst Russell Stanley says the most recent results were better than expected for The Cannabist Company (The Cannabist Company… [Read More]

3 hours ago

CSU stock is still undervalued, National Bank says

Following the company's first quarter results, National Bank Financial analyst Richard Tse has maintained his "Outperform" rating on Constellation Software… [Read More]

18 hours ago

Is TIXT stock a buy?

Its first quarter results are in the books and National Bank Financials analyst Richard Tse is feeling less bullish about… [Read More]

1 day ago

Is Jushi Holdings a buy?

Following the company's first quarter results, Echelon Capital Markets analyst Andrew Semple has maintained his "Hold" rating on Jushi Holdings… [Read More]

1 day ago